Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.
CAHON: Stop hate crimes and racism
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. We are proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
Aims and scope
Articles
-
-
Current insight into the regulation of PD-L1 in cancer
-
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin
-
JOSD2 regulates PKM2 nuclear translocation and reduces acute myeloid leukemia progression
-
A novel E-cadherin/SOX9 axis regulates cancer stem cells in multiple myeloma by activating Akt and MAPK pathways
-
Breast cancer brain metastases: the last frontier
-
COVID-19 vaccination associated severe immune thrombocytopenia
-
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
-
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
-
Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies
Editors-in-Chief
Delong Liu, New York Medical College
Kongming Wu, Tongji Medical Colleg
Editor's quote (Dr. Delong Liu)
"Like our companion journal, Journal of Hematology & Oncology, Experimental Hematology & Oncology publishes on all aspects of hematology and oncology, which are closely intertwined and rapidly evolving fields. It also emphasizes basic and translational research, as well as patient-oriented research and clinical trials with ‘negative’ or preliminary results. The journal is an international platform for sharing findings in these areas and adheres to fast turnaround times."
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Springer Nature Oncology Portfolio
Discover the range of academic oncology titles at Springer Nature here.
Follow
Annual Journal Metrics
-
Citation Impact
8.593 - 2-year Impact Factor (2021)
5.914 - 5-year Impact Factor (2021)
0.963 - Source Normalized Impact per Paper (SNIP)
1.223 - SCImago Journal Rank (SJR)Speed
6 days to first decision for all manuscripts (Median)
58 days to first decision for reviewed manuscripts only (Median)Usage
399,525 Downloads (2021)
443 Altmetric mentions (2021)
On the blog
-
Cancer champions – to the local community center… and beyond!
03 February 2022
-
-
Screening for kidney cancer in Leeds
16 April 2021
